Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
TECX 
Tectonic Therapeutic, Inc. (TECX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
11/28/2025: TECX (2-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Number of Analysts
6 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $78.71
1 Year Target Price $78.71
| 5 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 100.75% | Avg. Invested days 41 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  5.0 |
| Profits based on simulation | Last Close 11/28/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 401.28M USD | Price to earnings Ratio - | 1Y Target Price 78.71 |
Price to earnings Ratio - | 1Y Target Price 78.71 | ||
Volume (30-day avg) 6 | Beta - | 52 Weeks Range 13.70 - 61.07 | Updated Date 12/1/2025 |
52 Weeks Range 13.70 - 61.07 | Updated Date 12/1/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -2.69 |
Earnings Date
Report Date 2025-11-06 | When - | Estimate -0.13 | Actual -1.02 |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -21.46% | Return on Equity (TTM) -32.21% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 134080043 | Price to Sales(TTM) - |
Enterprise Value 134080043 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding 18716280 | Shares Floating 11147978 |
Shares Outstanding 18716280 | Shares Floating 11147978 | ||
Percent Insiders 38.38 | Percent Institutions 64.96 |
Upturn AI SWOT
Tectonic Therapeutic, Inc.
Company Overview
History and Background
Tectonic Therapeutic, Inc. is a biotechnology company focused on discovering and developing novel GPCR-targeted therapies. The company leverages its GEODe platform to identify and engineer antibodies against previously intractable GPCR targets.
Core Business Areas
- GPCR-targeted Antibody Discovery: Discovery and development of therapeutic antibodies targeting G protein-coupled receptors (GPCRs).
Leadership and Structure
Tectonic Therapeutic, Inc. has a management team with experience in drug discovery, antibody engineering, and clinical development.
Top Products and Market Share
Key Offerings
- GPCR Antibody Pipeline: Tectonic has not approved a product yet. However, they have an antibody pipeline of GPCR targeting antibodies in Preclinical stage. Competitors include major pharmaceutical companies pursuing similar GPCR targets but without Tectonic's specific technology.
Market Dynamics
Industry Overview
The biotechnology industry is highly competitive and rapidly evolving, with significant investment in innovative therapies. The GPCR targeted therapeutics is a growing field.
Positioning
Tectonic is positioned as an innovator in GPCR-targeted antibody therapeutics, leveraging its unique platform to address challenging targets.
Total Addressable Market (TAM)
The TAM for GPCR-targeted therapies is substantial, estimated at billions of dollars annually. Tectonic is positioned to capture a portion of this market through its innovative platform.
Upturn SWOT Analysis
Strengths
- Proprietary GEODe platform for GPCR antibody discovery
- Experienced management team
- Focus on challenging GPCR targets
- Strong intellectual property position
Weaknesses
- Preclinical stage pipeline
- Dependence on platform success
- High R&D expenses
- Limited clinical data
Opportunities
- Partnerships with pharmaceutical companies
- Expansion of GPCR target portfolio
- Advancement of pipeline candidates into clinical trials
- Potential for breakthrough therapies in underserved areas
Threats
- Competition from established pharmaceutical companies
- Clinical trial failures
- Regulatory hurdles
- Patent challenges
Competitors and Market Share
Key Competitors
- LLY
- ABBV
- MRK
- NVS
- PFE
Competitive Landscape
Tectonic's GEODe platform could provide a competitive advantage over companies using more traditional methods, but they are behind the other companies because they do not have any drugs approved yet.
Growth Trajectory and Initiatives
Historical Growth: N/A
Future Projections: Future growth is dependent on successful advancement of pipeline candidates.
Recent Initiatives: Focus on advancing preclinical candidates, generating validation data for the GEODe platform, and potentially seeking partnerships.
Summary
Tectonic Therapeutic is a biotechnology company with a unique platform for GPCR-targeted antibody discovery. As a private company in the preclinical stage, it is high-risk and high-reward. Its success hinges on the validation and advancement of its GPCR antibody pipeline. The company will need to be nimble to adapt to the quickly advancing market.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company website
- Industry reports
- Publicly available information
Disclaimers:
This analysis is based on limited publicly available information and should not be considered investment advice.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Tectonic Therapeutic, Inc.
Exchange NASDAQ | Headquaters Watertown, MA, United States | ||
IPO Launch date 2018-06-21 | President, CEO, Secretary & Director Dr. Alise S. Reicin M.D., Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 51 | Website https://tectonictx.com |
Full time employees 51 | Website https://tectonictx.com | ||
Tectonic Therapeutic, Inc., a biotechnology company, focuses on the discovery and development of therapeutic proteins and antibodies to modulate the activity of G protein-coupled receptors (GPCRs). It develops GEODe technology platform to enable the discovery and development of GPCR-targeted biologic medicines. The company's lead product is TX45, a Fc-relaxin fusion molecule that activates the RXFP1 receptor, the GPCR target of the hormone, and relaxin. It is also developing TX2100 for the treatment of hereditary hemorrhagic telangiectasia; GPCR modulator bispecific for treating fibrosis; and other GPCR modulators. The company is headquartered in Watertown, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.